Eloxx Pharmaceuticals, Inc.
Every calculator, already run for ELOX
Open the full toolkit →You have the numbers on ELOX. Get the argument.
A written report on which of these readings actually decide the outcome for Eloxx Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering ELOXAnalyst Price Target Disagreement for Eloxx Pharmaceuticals, Inc.
Wall Street's bull case implies +124% from the current price; the bear case implies +109%. Analysts are relatively aligned on ELOX's range.
Ownership & short interest
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration wit…
ELOX — frequently asked
Is ELOX a buy right now?
Wall Street's consensus rating on Eloxx Pharmaceuticals, Inc. is none across 2 analysts, with a mean price target of $41.50 (+116% vs. the current $19.18). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Eloxx Pharmaceuticals, Inc.?
Analysts covering Eloxx Pharmaceuticals, Inc. (ELOX) range from a bear-case target of $40.00 to a bull-case high of $43.00, with a mean consensus target of $41.50 across 2 analysts. The spread of $3.00 (16% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Eloxx Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Eloxx Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ELOX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Eloxx Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.